New emerging targets in cancer immunotherapy: the role of VISTA

Related Experiment Video

Updated: Dec 18, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K

Marco Tagliamento1, Paolo Bironzo2, Silvia Novello2

  • 1Department of Medical Oncology, Medical Oncology 2, University of Genova & IRCCS Ospedale Policlinico San Martino, Genova, Italy.

ESMO Open
|June 20, 2020
PubMed

Insights

New immunotherapy targets like V-domain Ig Suppressor of T-cell Activation (VISTA) show promise. CA-170, a VISTA and PD-L1 inhibitor, demonstrated clinical efficacy in advanced solid tumors, suggesting a potential new treatment option.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Immune checkpoint inhibitors (ICIs) are crucial in cancer therapy, but their efficacy is limited by biomarkers like PD-L1.
  • Novel therapeutic targets and biomarkers are essential to enhance immunotherapy outcomes.
  • V-domain Ig Suppressor of T-cell Activation (VISTA) is a key regulator of T-cell responses with emerging antitumour potential.

Purpose of the Study:

  • To explore VISTA as a therapeutic target for cancer immunotherapy.
  • To evaluate the clinical efficacy and potential of VISTA antagonists, specifically CA-170.

Main Methods:

  • Preclinical studies investigating VISTA blockade for antitumour activity.
  • Phase I and II clinical trials of CA-170, an oral dual VISTA and PD-L1 inhibitor, in patients with advanced solid tumors.

Main Results:

  • VISTA blockade demonstrated in vitro and in vivo antitumour activity.
  • CA-170 exhibited clinical efficacy across various advanced solid tumor types in early-phase trials.
  • The drug is an orally delivered dual inhibitor targeting both VISTA and PD-L1.

Conclusions:

  • VISTA represents a promising target for novel cancer immunotherapies.
  • CA-170 shows potential as a new therapeutic option for patients with VISTA-expressing cancers.
  • Further clinical data are required to establish VISTA antagonists as a standard treatment modality.
Keywords:
VISTAbiomarkerscancerimmune checkpointimmunotherapy

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
867
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K